Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
BMS 986278 is an antagonist of lysophosphatidic acid receptor 1 (LPA1; Kb = 0.0069 µM).1 It is selective for LPA1 over a panel of 44 receptors, ion channels, and enzymes when used at concentrations ranging from 30 to 150 µM, including the bile salt export pump (BSEP), multidrug resistance protein 3 (MDR3), multidrug resistance-associated protein 3 (MRP3), MRP4, organic anion transporting polypeptide 1B1 (OATP1B1), and OATP1B3 (IC50s = >100, >100, 66, 47, 36, and 10 µM, respectively). BMS 986278 inhibits LPA-induced histamine release in mice in a dose-dependent manner. Oral administration of BMS 986278 (3 and 10 mg/kg) reduces bleomycin-induced lung fibrosis in rats. Unlike BMS 986020 (Item No. 22049), BMS 986278 does not induce bile duct hyperplasia, cholangitis, or cholestasis in cynomolgus monkeys.2
WARNING This product is not for human or veterinary use.
1. Discovery of an oxycyclohexyl acid lysophosphatidic acid receptor 1 (LPA1) antagonist BMS-
2. Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA1) antagonists. Toxicol. Appl. Pharmacol. 438, 115846 (2021).